ACADIA Current Deferred Revenue vs Property Plant And Equipment Net Analysis
ACAD Stock | USD 15.25 0.04 0.26% |
ACADIA Pharmaceuticals financial indicator trend analysis is way more than just evaluating ACADIA Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ACADIA Pharmaceuticals is a good investment. Please check the relationship between ACADIA Pharmaceuticals Current Deferred Revenue and its Property Plant And Equipment Net accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
Current Deferred Revenue vs Property Plant And Equipment Net
Current Deferred Revenue vs Property Plant And Equipment Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ACADIA Pharmaceuticals Current Deferred Revenue account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have no relationship.
The correlation between ACADIA Pharmaceuticals' Current Deferred Revenue and Property Plant And Equipment Net is 0.06. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of ACADIA Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ACADIA Pharmaceuticals' Current Deferred Revenue and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of ACADIA Pharmaceuticals are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Current Deferred Revenue i.e., ACADIA Pharmaceuticals' Current Deferred Revenue and Property Plant And Equipment Net go up and down completely randomly.
Correlation Coefficient | 0.06 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most indicators from ACADIA Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 1.8 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.51.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 465.0M | 507.1M | 680.7M | 714.7M | Total Revenue | 484.1M | 517.2M | 726.4M | 762.8M |
ACADIA Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
ACADIA Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ACADIA Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 783.2M | 782.6M | 700.1M | 587.8M | 749.0M | 786.4M | |
Total Stockholder Equity | 699.1M | 627.0M | 540.9M | 400.4M | 431.8M | 232.8M | |
Net Debt | (183.3M) | (281.6M) | (91.3M) | (52.8M) | (131.5M) | (124.9M) | |
Other Assets | 5.3M | 54.7M | 16.0M | 11.1M | 12.7M | 7.9M | |
Common Stock Shares Outstanding | 147.2M | 157.3M | 160.5M | 161.7M | 163.8M | 172.0M | |
Liabilities And Stockholders Equity | 783.2M | 782.6M | 700.1M | 587.8M | 749.0M | 786.4M | |
Non Current Liabilities Total | 9.2M | 49.6M | 63.2M | 61.8M | 62.9M | 66.1M | |
Other Stockholder Equity | 2.4B | 2.6B | 2.7B | 2.8B | 2.9B | 3.0B | |
Total Liab | 84.0M | 155.6M | 159.2M | 187.4M | 317.2M | 333.1M | |
Other Current Liab | 64.2M | 92.4M | 80.9M | 103.6M | 225.7M | 237.0M | |
Total Current Liabilities | 74.8M | 106.0M | 96.1M | 125.6M | 254.3M | 267.0M | |
Property Plant And Equipment Net | 12.7M | 56.4M | 66.3M | 61.6M | 56.5M | 59.3M | |
Retained Earnings | (1.7B) | (2.0B) | (2.2B) | (2.4B) | (2.4B) | (2.3B) | |
Accounts Payable | 7.2M | 8.5M | 6.9M | 12.7M | 17.5M | 18.4M | |
Cash | 189.7M | 326.0M | 147.4M | 114.8M | 188.7M | 198.1M | |
Non Current Assets Total | 22.9M | 65M | 82.3M | 79.9M | 132.8M | 139.5M | |
Non Currrent Assets Other | 7.6M | 7.4M | 6.6M | 5.3M | 5.1M | 2.6M | |
Cash And Short Term Investments | 697.4M | 632.0M | 520.7M | 416.8M | 438.9M | 269.3M | |
Short Term Investments | 507.7M | 305.9M | 373.3M | 302.0M | 250.2M | 185.1M | |
Other Current Assets | 18.6M | 25.7M | 23.9M | 21.4M | 39.1M | 41.0M | |
Property Plant And Equipment Gross | 12.7M | 56.4M | 66.3M | 61.6M | 66.0M | 69.3M | |
Total Current Assets | 760.3M | 717.6M | 617.8M | 507.9M | 616.1M | 646.9M | |
Accumulated Other Comprehensive Income | 297K | 36K | (192K) | (975K) | 24K | 25.2K | |
Property Plant Equipment | 3.2M | 9.2M | 66.3M | 61.6M | 70.8M | 74.4M | |
Other Liab | 2.9M | 5.2M | 7.0M | 9.1M | 10.4M | 11.0M | |
Net Tangible Assets | 696.6M | 625.9M | 540.9M | 400.4M | 460.5M | 403.1M | |
Retained Earnings Total Equity | (1.5B) | (1.7B) | (2.0B) | (2.2B) | (1.9B) | (1.8B) | |
Capital Surpluse | 1.9B | 2.4B | 2.6B | 2.7B | 3.1B | 1.6B | |
Inventory | 6.3M | 9.7M | 7.9M | 6.6M | 35.8M | 37.6M | |
Intangible Assets | 4.1M | 2.6M | 1.1M | 65.5M | 75.3M | 79.1M | |
Net Receivables | 37.9M | 50.3M | 65.3M | 63.1M | 102.4M | 107.5M | |
Non Current Liabilities Other | 9.2M | 49.6M | 7.0M | 9.1M | 15.1M | 12.7M | |
Net Invested Capital | 699.1M | 627.0M | 540.9M | 400.4M | 431.8M | 401.6M | |
Net Working Capital | 685.4M | 611.6M | 521.8M | 382.3M | 361.9M | 383.3M |
ACADIA Pharmaceuticals Investors Sentiment
The influence of ACADIA Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ACADIA. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ACADIA Pharmaceuticals' public news can be used to forecast risks associated with an investment in ACADIA. The trend in average sentiment can be used to explain how an investor holding ACADIA can time the market purely based on public headlines and social activities around ACADIA Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ACADIA Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ACADIA Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ACADIA Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on ACADIA Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ACADIA Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ACADIA Pharmaceuticals' short interest history, or implied volatility extrapolated from ACADIA Pharmaceuticals options trading.
Pair Trading with ACADIA Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ACADIA Stock
0.76 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
0.72 | EPIX | ESSA Pharma Financial Report 14th of May 2024 | PairCorr |
Moving against ACADIA Stock
0.75 | AZN | AstraZeneca PLC ADR | PairCorr |
0.67 | XFOR | X4 Pharmaceuticals | PairCorr |
0.62 | ERNA | Eterna Therapeutics | PairCorr |
0.58 | OPT | Opthea | PairCorr |
0.52 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 4.949 | Quarterly Revenue Growth 0.738 | Return On Assets (0) | Return On Equity (0) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.